- Home
- ABOS vs CRVO Comparison
ABOS vs CRVO Comparison
Compare ABOS & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABOS | CRVO |
|---|---|---|
| Founded | 1996 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.9M | 78.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ABOS | CRVO |
|---|---|---|
| Price | $1.83 | $7.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $7.67 | ★ $21.50 |
| AVG Volume (30 Days) | ★ 175.4K | 45.1K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,159,786.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.86 | $1.92 |
| 52 Week High | $2.46 | $16.94 |
Technical Indicators
Market Signals| Indicator | ABOS | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 40.89 | 42.86 |
| Support Level | $1.90 | $7.43 |
| Resistance Level | $2.39 | $8.46 |
| Average True Range (ATR) | 0.15 | 0.51 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 14.93 | 23.02 |
Price Performance
Historical ComparisonAbout ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.